Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Do‐Youn Oh(Seoul National University Hospital), Juan W. Valle(Cancer Research UK Manchester Institute), Suebpong Tanasanvimon(Thai Red Cross Society), Masafumi Ikeda(National Cancer Center Hospital East), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Julie Wang(Shanghai Jiao Tong University), Mairéad G. McNamara(Australian and New Zealand Intensive Care Society), Aiwu Ruth He(Georgetown University), John F. Kurland(AstraZeneca (Netherlands)), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Arndt Vogel(Medizinische Hochschule Hannover), Hidenori Takahashi(Osaka International Cancer Institute), Howard A. Burris(Deaconess Hospital), Takuji Okusaka(National Cancer Centre Japan), Renata Zaucha(Gdańsk Medical University), Shukui Qin(Memorial Sloan Kettering Cancer Center), Mohamed Bouattour(Hôpital Beaujon), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Philip He(AstraZeneca (Japan)), Jin Won Kim(Seoul National University Bundang Hospital), Li‐Tzong Chen(Kaohsiung Medical University), Masayuki Kitano(Wakayama Medical University), Benjamin Tan(Washington University in St. Louis), Nana Rokutanda(AstraZeneca (Japan)), Juan Cundom, Thatthan Suksombooncharoen(Chiang Mai University), Mallory Makowsky(AstraZeneca (Japan)), Gordon Cohen(AstraZeneca (Japan)), Choong‐kun Lee(Yonsei University)
Cited by 1,078
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k